Work

Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer

Year: 2011

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2011.05.014

Authors: Jamie L. Lesnock, Coreen Farris, Thomas C. Krivak, Kenneth J. Smith, Maurie Markman

Institutions: Magee-Womens Hospital, University of Pittsburgh Medical Center, University of Pittsburgh, Cancer Treatment Centers of America

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Center for Research Resources, National Center for Advancing Translational Sciences

Awards: University of Pittsburgh Clinical and Translational Science Institute, University of Pittsburgh Clinical and Translational Science Institute

OpenAlex ID: W1966754084

FWCI: 7.165

Cites: 43

Cited by: 40

Related to: 10